Sarepta halted, pending news, ahead of FDA decision on SRP-9001

Previously, on May 24, Sarepta Therapeutics provided an update on the Biologics License Application for SRP-9001, or delandistrogene moxeparvovec, which is currently under review for the treatment of ambulant individuals with Duchenne muscular dystrophy or DMD, who have a confirmed mutation of the DMD gene. “Following discussions with FDA, the Agency has indicated that, subject to the completion of the BLA review, it is working toward potentially granting an accelerated approval for SRP-9001, initially for use in Duchenne patients ages 4-5 years old. EMBARK, the global, randomized, double-blind, placebo-controlled Phase 3 trial of SRP-9001, is the proposed confirmatory study. The Agency has informed Sarepta that, in addition to confirming the results of the initial BLA approval, if the trial meets its objectives the Agency intends to entertain a non-age-restricted expansion of the SRP-9001 label based upon the review of the EMBARK data… The FDA has also informed Sarepta that it requires modest additional time to complete the review, including final label negotiations and post marketing commitment discussions, and that it anticipates that the review will be complete by June 22. Sarepta will remain in a quiet period for the duration of the BLA review.”